Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-17 pm EST			5-day change	1st Jan Change
725.72 ^USD	-4.21%		-9.00%	-5.99%

Jan. 17	S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	MT
Jan. 17	What Wegovy's inclusion in Medicare price negotiation means for patients, company	RE

Analyst Reco.

Guggenheim Adjusts Price Target on Eli Lilly to $973 From $995, Maintains Buy Rating	Jan. 17	MT
Berenberg Bank Adjusts Eli Lilly Price Target to $970 From $1,050, Maintains Buy Rating	Jan. 16	MT
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating	Jan. 16	MT
Leerink Partners Adjusts Price Target on Eli Lilly to $950 From $970, Keeps Outperform Rating	Jan. 15	MT
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994	Jan. 14	MT
ELI LILLY AND COMPANY : Jefferies gives a Buy rating	Dec. 20	ZD
Eli Lilly: conclusive phase III trial on tirzepatide	Nov. 14	CF
Daiwa Adjusts Price Target on Eli Lilly & Co. to $900 From $940, Maintains Outperform Rating	Nov. 12	MT
CICC Adjusts Price Target on Eli Lilly & Co. to $832 From $920.20, Maintains Neutral Rating	Nov. 11	MT
Redburn Atlantic Adjusts Price Target on Eli Lilly to $700 From $640, Maintains Neutral Rating	Nov. 04	MT
Deutsche Bank Cuts Price Target on Eli Lilly to $1,015 From $1,025, Buy Rating Maintained	Nov. 01	MT
Guggenheim Adjusts Price Target on Eli Lilly to $995 From $955	24-10-31	MT
BofA Securities Adjusts Price Target on Eli Lilly to $1,100 From $1,150, Maintains Buy Rating	24-10-31	MT
ELI LILLY AND COMPANY : Jefferies remains its Buy rating	24-10-31	ZD
Leerink Adjusts Price Target on Eli Lilly to $970 From $990, Maintains Outperform Rating	24-10-31	MT
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating	24-10-31	MT
Barclays Adjusts Price Target on Eli Lilly to $975 From $1,025	24-10-31	MT
Truist Securities Adjusts Price Target on Eli Lilly and Co. to $1,029 From $1,033, Maintains Buy Rating	24-10-31	MT
Guggenheim Adjusts Price Target on Eli Lilly and Co. to $955 From $1,024, Maintains Buy Rating	24-10-31	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,146 From $1,158, Maintains Overweight Rating	24-10-31	MT
BMO Capital Adjusts Price Target on Eli Lilly and Co. to $1,010 From $1,101, Maintains Outperform Rating	24-10-31	MT
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $890 From $856	24-10-21	MT
Bernstein Initiates Coverage on Eli Lilly With Outperform Rating, $1,100 Price Target	24-10-17	MT
Today's stock recommendations at a glance	24-10-17	FW
Guggenheim Adjusts Price Target on Eli Lilly & Co. to $1,024 From $884, Maintains Buy Rating	24-10-14	MT

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

January 13, 2025 at 11:30 am EST